Export this record

Export record to excel

File type to download

Beta version

Select record 1

ArticlesPeer ReviewedFull Text

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3...

Author / Creator:Platzbecker, Uwe ; Della Porta, Matteo Giovanni ; Santini, Valeria ; Zeidan, Amer M ; Komrokji, Rami S ; Shortt, Jake ; Valcarcel, David ; Jonasova, Anna ; Dimicoli-Salazar, Sophie ; Tiong, Ing Soo ; Lin, Chien-Chin ; Li, Jiahui ; Zhang, Jennie ; Giuseppi, Ana Carolina ; Kreitz, Sandra ; Pozharskaya, Veronika ; Keeperman, Karen L ; Rose, Shelonitda ; Shetty, Jeevan K ; Hayati, Sheida ; Vodala, Sadanand ; Prebet, Thomas ; Degulys, Andrius ; Paolini, Stefania ; Cluzeau, Thomas ; Fenaux, Pierre ; Garcia-Manero, Guillermo

Publisher:England: Elsevier Ltd

Journal title:The Lancet (British edition), 2023-07, Vol.402 (10399), p.373-385

View online as a Library member

Export record to excel

Export this record

Export record to excel

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3...

Export this record

Export record to excel

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring side...

Refine your search